Loading
A phase 2 trial of durvalumab and tremelimumab in gallbladder cancer and other biliary tract cancers, run by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, active and no longer recruiting.
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) is a phase 2, randomised interventional study registered as NCT04238637 by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, with a registry enrolment figure of 50 participants, started 2019-11-01 and due to reach its primary completion in 2026-08. Interventions recorded: Durvalumab, Tremelimumab. Conditions listed: Intrahepatic Cholangiocarcinoma. Sites: Germany. No results are recorded here; the registry entry is the source.
Shares Tremelimumab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab and the tag gallbladder-deep-dive.
Shares Tremelimumab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab and the tag gallbladder-deep-dive.
Shares Tremelimumab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab and the tag gallbladder-deep-dive.